Get the Stockscreener App
26.05
2.51%
-0.67
After Hours:
26.05
Capricor Therapeutics Inc stock is traded at $26.05, with a volume of 654.84K.
It is down -2.51% in the last 24 hours and down -9.52% over the past month.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
See More
Previous Close:
$26.72
Open:
$26.8
24h Volume:
654.84K
Relative Volume:
0.59
Market Cap:
$1.51B
Revenue:
$11.13M
Net Income/Loss:
$-114.59M
P/E Ratio:
-11.26
EPS:
-2.313
Net Cash Flow:
$-113.96M
1W Performance:
+0.15%
1M Performance:
-9.52%
6M Performance:
+0.12%
1Y Performance:
+110.42%
1-Day Range:
$25.60
$27.07
1-Week Range:
$24.65
$27.07
52-Week Range:
$4.30
$40.37
Capricor Therapeutics Inc Stock (CAPR) Company Profile
Name
Capricor Therapeutics Inc
Sector
Industry
Phone
(310) 358-3200
Address
10865 ROAD TO THE CURE, SAN DIEGO, CA
Compare CAPR vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
26.05 | 1.55B | 11.13M | -114.59M | -113.96M | -2.313 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-30-25 | Initiated | Alliance Global Partners | Buy |
| Jun-26-25 | Initiated | B. Riley Securities | Buy |
| May-20-25 | Initiated | Roth Capital | Buy |
| Oct-21-24 | Initiated | Piper Sandler | Overweight |
| May-17-24 | Initiated | Oppenheimer | Outperform |
| Jan-05-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-26-22 | Initiated | Ladenburg Thalmann | Buy |
| Dec-26-18 | Downgrade | Maxim Group | Buy → Hold |
| Jan-26-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-15-17 | Reiterated | H.C. Wainwright | Buy |
| Feb-13-17 | Resumed | Rodman & Renshaw | Buy |
| Jul-06-16 | Resumed | H.C. Wainwright | Buy |
| Jun-15-16 | Initiated | ROTH Capital | Buy |
View All
Capricor Therapeutics Inc Stock (CAPR) Latest News
CAPR Stock Sinks After-Hours: Capricor Launches Legal Fight Over DMD Therapy Rollout Ahead Of FDA Review - Stocktwits
CAPR Stock Gains Steam: Former Capricor Exec Could Become FDA’s Top Gene Therapy Regulator Ahead Of High-Stakes DMD Decision - Stocktwits
Capricor Therapeutics eyes FDA approval path for Duchenne cell therapy - MSN
Capricor Therapeutics Eyes FDA Approval Path for Duchenne Cell Therapy - MarketBeat
Capricor Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Capricor Or Sarepta: Two DMD Stocks Enter A High-Stakes Week – Which One Has More Upside? - Stocktwits
Trading Systems Reacting to (CAPR) Volatility - Stock Traders Daily
CAPR Stock Draws Investor Attention After AAN Presentation For DMD Therapy - Stocktwits
CAPR Stock In Spotlight As Investors Eye Next Week’s DMD Trial Data Showing Muscle And Cardiac Gains - Stocktwits
CAPR Stock Heads For Best Week In Nearly A Month: CEO Says 'No Way' Deramiocel Gets Only Conditional Approval - Stocktwits
Capricor (NASDAQ: CAPR) reports 2026 shareholder meeting vote tallies - Stock Titan
Capricor Therapeutics to Present at Upcoming Investor Conferences - The Manila Times
Capricor Therapeutics to Participate in Upcoming Investor Conferences in Miami - Quiver Quantitative
CAPR Stock Slumps But Wall Street Reiterates Optimism For Deramiocel Approval - Stocktwits
Capricor Therapeutics Boosts FDA Approval Preparation for Deramiocel - HarianBasis.co
Deramiocel Outlook Strengthens Capricor Therapeutics, Inc. (CAPR) as a Small-Cap Stock to Buy - Insider Monkey
CAPR Stock Surged 17% Today — What’s Fueling The Rally? - Stocktwits
5 Most Shorted Mid-Cap and Small-Cap Stocks to Buy Now - Insider Monkey
Assessing Capricor Therapeutics (CAPR) Valuation After Recent Share Price Cooling And Phase 3 Progress - Sahm
Capricor: I Rate It A Buy After Stress-Testing The Sell Thesis - Seeking Alpha
Capricor Shares Fall, FDA Call in August Looms - Bez Kabli
US Biotech Co. Targets Muscular Dystrophy with First-In-Class Drug - Streetwise Reports
Capricor expands commercial leadership team - The Pharma Letter
What is the latest on Capricor Therapeutics' Deramiocel and its FDA journey - Kavout
Replimune takes third swing at cancer drug approval following ‘productive’ FDA talks - BioPharma Dive
How Capricor Therapeutics Inc. (CAPR) Affects Rotational Strategy Timing - Stock Traders Daily
symbol__ Stock Quote Price and Forecast - CNN
CAPR Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Advances PipelineNext Quarter Guidance - thelegaladvocate.com
Capricor Therapeutics (CAPR) names CCO Michael Maurer as SEC reporting insider - Stock Titan
Capricor (CAPR) CCO Michael Maurer awarded 80,000 stock options at $29.36 - Stock Titan
NeoVolta (NEOV) Q1 2026 Earnings: EPS Beats Estimates Despite Revenue Absence, Stock Drops 23.64%Earnings Surprise Report - thelegaladvocate.com
Capricor Therapeutics (CAPR) Slips Slightly as Stock Consolidates Near Key ResistanceFloat Adjusted Cap - thelegaladvocate.com
‘Pharma Bro’ Martin Shkreli Calls His Capricor Therapeutics Short A 'Bad Call' After DMD Trial Delivers Surprise Win - MSN
Duchenne Muscular Dystrophy Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape - GlobeNewswire Inc.
CAPR Stock Price, Quote & Chart | CAPRICOR THERAPEUTICS INC (NASDAQ:CAPR) - ChartMill
Capricor drops following filing of lawsuit against Nippon Shinyaku - MSN
A Look At Capricor Therapeutics (CAPR) Valuation After Deramiocel Launch Delay And Milestone Cut - Sahm
Tesla Launches Full Self-Driving (Supervised) in China Amid Intensifying EV CompetitionRevenue Report - thelegaladvocate.com
United States Duchenne Muscular Dystrophy Therapeutics Market - openPR.com
How Investors May Respond To Capricor Therapeutics (CAPR) Deramiocel Regulatory Uncertainty After Wider Q1 Loss - Sahm
Capricor Therapeutics says NS Pharma delays could threaten access to Duchenne therapy - MSN
Should you sell your Capricor Therapeutics stock? - Cantech Letter
Capricor’s Earnings Call: Deramiocel Drives High-Stakes Pivot - TipRanks
CAPR stock sinks after-hours: Capricor launches legal fight over DMD therapy rollout ahead of FDA review - MSN
Capricor Therapeutics Inc Stock (CAPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.27%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):